[1]
|
彭玲, 焦丰叶, 陈丽霞. 甲状腺结节的诊断与治疗研究现状[J]. 医药论坛杂志, 2023(2): 97-101.
|
[2]
|
甲状腺癌诊疗指南(2022年版) [J]. 中国实用外科杂志, 2022(12): 1343-1357, 1363.
|
[3]
|
邓龙, 马苏美. 甲状腺结节良恶性诊断现状分析[J]. 临床超声医学杂志, 2018, 20(5): 336-339.
|
[4]
|
Boers, T., Braak, S.J., Rikken, N.E.T., Versluis, M. and Manohar, S. (2023) Ultrasound Imaging in Thyroid Nodule Diagnosis, Therapy, and Follow-Up: Current Status and Future Trends. Journal of Clinical Ultrasound, 51, 1087-1100.
https://doi.org/10.1002/jcu.23430
|
[5]
|
中华医学会超声医学分会浅表器官和血管学组, 中国甲状腺与乳腺超声人工智能联盟. 2020甲状腺结节超声恶性危险分层中国指南: C-TIRADS [J]. 中华超声影像学杂志, 2021, 30(3): 185-200.
|
[6]
|
张渊, 江泉, 陈剑, 等. 甲状腺单发结节三维超声定性诊断及其ROC曲线分析[J]. 中国临床医学影像杂志, 2010, 21(1): 13-16.
|
[7]
|
徐甫, 肖仕琪, 邱华文, 等. 三维超声成像在甲状腺复杂结节定性诊断的价值与细针穿刺组织活检对比[J]. 中国医疗前沿, 2012, 7(11): 62-63.
|
[8]
|
Zhang, Y., Luo, Y.K., Zhang, M.B., et al. (2016) Diagnostic Accuracy of Contrast-Enhanced Ultrasound Enhancement Patterns for Thyroid Nodules. Medical Science Monitor, 22, 4755-4764. https://doi.org/10.12659/MSM.899834
|
[9]
|
Luo, W., Yang, X., Yuan, J.N., et al. (2020) Evaluation of Characteristics of Thyroid Nodules on Contrast-Enhanced Ultrasonography: A Retrospective Anal-ysis of 252 Cases. Medical Ultrasonography, 22, 164-170.
https://doi.org/10.11152/mu-2252
|
[10]
|
Chen, F., Han, H.J., Wan, P., et al. (2023) Joint Segmentation and Differ-ential Diagnosis of Thyroid Nodule in Contrast-Enhanced Ultrasound Images. IEEE Transactions on Biomedical Engi-neering, 70, 2722-2732.
|
[11]
|
Xing, P., Wu, L.F., Zhang, C.M., et al. (2011) Differentiation of Benign from Malignant Thyroid Lesions: Calculation of the Strain Ratio on Thyroid Sonoelastography. Journal of Ultrasound in Medicine, 30, 663-669.
https://doi.org/10.7863/jum.2011.30.5.663
|
[12]
|
陈学敏, 胡明军, 何年安. 67505例甲状腺结节超声检查结果分析[J]. 安徽医学, 2023, 44(10): 1227-1230.
|
[13]
|
崔楠, 陈雨凡, 柏通, 等. 甲状腺结节AI超声辅助诊断系统在住院医师规范化培训教学中的应用[J]. 中国医学物理学杂志, 2023, 40(10): 1233-1236.
|
[14]
|
Zheng, G.B., Zhang, H.C., Lin, F.S., et al. (2023) Performance of CT-Based Deep Learning in Diagnostic Assessment of Suspicious Lateral Lymph Nodes in Papillary Thyroid Cancer: A Prospective Diagnostic Study. International Journal of Surgery, 109, 3337-3345.
|
[15]
|
Huang, N.S., Li, Q., Gao, X.Y., et al. (2023) Using a CT-Based Scale to Evaluate Disease Extension and the Resectability of Locally Advanced Thyroid Cancer. European Radiology, 33, 9063-9073.
|
[16]
|
魏来, 王伟, 董慧玲, 等. CT对甲状腺结节钙化良恶性的鉴别作用分析[J]. 中国CT和MRI杂志, 2023, 21(2): 46-48.
|
[17]
|
邵旭辉, 张军胜, 张华文, 等. 应用CT、MRI检查对甲状腺结节性质的鉴别诊断价值比较[J]. 中国CT和MRI杂志, 2021, 19(11): 32-34.
|
[18]
|
安静. CT、MRI在甲状腺良恶性结节诊断中的价值分析[J]. 中国医疗器械信息, 2023, 29(10): 93-95.
|
[19]
|
Golbert, L., de Cristo, A.P., Faccin, C.S., et al. (2017) Serum TSH Levels as a Predictor of Malig-nancy in Thyroid Nodules: A Prospective Study. PLOS ONE, 12, e0188123. https://doi.org/10.1371/journal.pone.0188123
|
[20]
|
Rivas, M. and Santisteban, P. (2003) TSH-Activated Signaling Pathways in Thyroid Tumorigenesis. Molecular and Cellular Endocrinology, 213, 31-45. https://doi.org/10.1016/j.mce.2003.10.029
|
[21]
|
Cappelli, C., Pirola, I., Gandossi, E., et al. (2020) Could Serum TSH Levels Predict Malignancy in Euthyroid Patients Affected by Thyroid Nodules with Indeterminate Cytology? Inter-national Journal of Endocrinology, 2020, Article ID: 7543930. https://doi.org/10.1155/2020/7543930
|
[22]
|
Amado, A., Castro, B., Torre, A.P., et al. (2022) Serum TSH as a Predictor of Malignancy in Indeterminate Thyroid Nodules. The Annals of the Royal College of Surgeons of England, 104, 380-384.
https://doi.org/10.1308/rcsann.2021.0196
|
[23]
|
杨媛媛, 陈源清, 游琴秀. 血清TSH、TPO-Ab、Tg-Ab水平在良恶性甲状腺结节诊断中的意义[J]. 黑龙江医药科学, 2023, 46(3): 79-81.
|
[24]
|
Murata, M. (2018) Inflammation and Cancer. Environmental Health and Preventive Medicine, 23, Article No. 50.
https://doi.org/10.1186/s12199-018-0740-1
|
[25]
|
Aktas, G., Sit, M., Karagoz, I., et al. (2017) Could Red Cell Dis-tribution Width be a Marker of Thyroid Cancer? Journal of College of Physicians and Surgeons Pakistan, 27, 556-558.
|
[26]
|
Cheong, T.Y., Hong, S.D., Jung, K.W., et al. (2021) The Diagnostic Predictive Value of Neutro-phil-to-Lymphocyte Ratio in Thyroid Cancer Adjusted for Tumor Size. PLOS ONE, 16, e0251446.
https://doi.org/10.1371/journal.pone.0251446
|
[27]
|
Kimura, E.T., Nikiforova, M.N., Zhu, Z., et al. (2003) High Prevalence of BRAF Mutations in Thyroid Cancer: Genetic Evidence for Constitutive Activation of the RET/PTC-RAS-BRAF Signaling Pathway in Papillary Thyroid Carcinoma. Cancer Research, 63, 1454-1457.
|
[28]
|
Raffaele, C. and Nikiforov, Y.E. (2005) Alterations of the BRAF Gene in Thyroid Tumors. Endocrine Pathology, 16, 163-171. https://doi.org/10.1385/EP:16:3:163
|
[29]
|
Xing, M. (2005) BRAF Mutation in Thyroid Cancer. Endocrine-Related Cancer, 12, 245-262.
https://doi.org/10.1677/erc.1.0978
|
[30]
|
Nikiforova, M.N. and Nikiforov, Y.E. (2009) Molecular Diagnostics and Predictors in Thyroid Cancer. Thyroid, 19, 1351-1361. https://doi.org/10.1089/thy.2009.0240
|
[31]
|
Fusco, A., Grieco, M., Santoro, M., et al. (1987) A New Oncogene in Human Thyroid Papillary Carcinomas and Their Lymph-Nodal Metastases. Nature, 328, 170-172. https://doi.org/10.1038/328170a0
|
[32]
|
Karga, H., Lee, J.K., Vickery Jr., A.L., et al. (1991) Ras Oncogene Mutations in Benign and Malignant Thyroid neOplasms. The Journal of Clinical Endocrinology and Metabolism, 73, 832-836. https://doi.org/10.1210/jcem-73-4-832
|
[33]
|
Namba, H., Ru-bin, S.A. and Fagin, J.A. (1990) Point Mutations of Ras Oncogenes Are an Early Event in Thyroid Tumorigenesis. Mo-lecular Endocrinology, 4, 1474-1479. https://doi.org/10.1210/mend-4-10-1474
|
[34]
|
Zhu, Z.W., Gandhi, M., Niki-forova, M.N., Fischer, A.H. and Nikiforov, Y.E. (2003) Molecular Profile and Clinical-Pathologic Features of the Follic-ular Variant of Papillary Thyroid Carcinoma: An Unusually High Prevalence of Ras Mutations. American Journal of Clinical Pathology, 120, 71-77. https://doi.org/10.1309/ND8D9LAJTRCTG6QD
|
[35]
|
Suarez, H.G., du Villard, J.A., Severino, M., et al. (1990) Presence of Mutations in All Three Ras Genes in Human Thyroid Tumors. Oncogene, 5, 565-570.
|
[36]
|
Motoi, N., Sakamoto, A., Yamochi, T., et al. (2000) Role of Ras Mutation in the Progression of Thyroid Carcinoma of Follicular Epithelial Origin. Pathology-Research and Practice, 196, 1-7.
https://doi.org/10.1016/S0344-0338(00)80015-1
|
[37]
|
Schark, C., Fulton, N., Jacoby, R.F., et al. (1990) N-Ras 61 Oncogene Mutations in Hürthle Cell Tumors. Surgery, 108, 994-999.
|
[38]
|
Tallini, G., Hsueh, A., Liu, S., et al. (1999) Frequent Chromosomal DNA Unbalance in Thyroid Oncocytic (Hürthle Cell) Neoplasms Detected by Comparative Ge-nomic Hybridization. Laboratory Investigation, 79, 547-555.
|
[39]
|
Basolo, F., Pisaturo, F., Pollina, L.E., et al. (2000) N-Ras Mutation in Poorly Differentiated Thyroid Carcinomas: Correlation with Bone Metastases and Inverse Correlation to Thyroglobulin Expression. Thyroid, 10, 19-23.
https://doi.org/10.1089/thy.2000.10.19
|
[40]
|
Ginesa, G.R., Hongyu, Z., Camp, R.L., et al. (2003) Ras Mutations Are Associated with Aggressive Tumor Phenotypes and Poor Prognosis in Thyroid Cancer. Journal of Clinical Oncolo-gy, 21, 3226-3235.
https://doi.org/10.1200/JCO.2003.10.130
|